Impact of refitted race-free eGFR formula on obesity pharmacotherapy options.

Babak J OrandiChandler McLeodRhiannon D ReedVineeta KumarLeon I IgelLouis J AronneRobert M CannonCora Elizabeth LewisJayme E Locke

Published in: Obesity (Silver Spring, Md.) (2022)

These findings highlight the importance of measuring-rather than estimating-GFR in Black people with CKD when considering many antiobesity pharmacotherapy options.

Keyphrases

smoking cessation
small cell lung cancer
insulin resistance
metabolic syndrome
weight loss
chronic kidney disease
epidermal growth factor receptor
type diabetes
tyrosine kinase
high fat diet induced
human milk
adipose tissue
skeletal muscle
physical activity
preterm infants
low birth weight